Press Releases

Press Releases

April 15, 2019
Anti-BCMA AlloCAR T Cells Maintained Phenotype and Sustained Potent Anti-Tumor Responses After Scaled-Up Manufacturing ALLO-715 Investigational New Drug Application and Phase 1 Trial Initiation Expected in 2019 SOUTH SAN FRANCISCO, Calif. , April 15, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics,
April 3, 2019
SOUTH SAN FRANCISCO, Calif. , April 03, 2019 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced that management plans to present at the Jefferies
Displaying 11 - 18 of 18
Print Page
E-mail Alerts
RSS
Investor Contacts